

### **REMARKS/ARGUMENTS**

Claims 1-92 are pending. The Examiner has imposed a Restriction Requirement between:

Group I: Claims 1-20, drawn to a research model for screening compounds suspected of modulating the CD40L/CD40R signaling pathway;

Group II: Claims 21-39, drawn to a research model for screening compounds suspected of modulating the CD40L/CD40R signaling pathway;

Group III: Claims 40-53, drawn to a method of identifying compounds that ameliorate symptoms associated with a disease;

Group IV: Claims 54-70, drawn to a method of treating a disease; and

Group V: Claims 71-92, drawn to a method of causing a desired biological effect.

Applicant elects Group I, claims 1-20, without traverse.


Applicant further elects the following species for examination:

- A. animal;
- B. cells: central nervous system cells;
- C. marker: cytokine and in particular tumor necrosis factor;
- D. compound: a compound that binds to CD40L; and
- E. disease: neuronal inflammation.

Claims readable on the elected species include claims 1-4, 8, 16 and 19-20.

Examination of the elected claims is respectfully requested. The Commissioner is authorized to charge any additional fees, or to credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

By:   
\_\_\_\_\_  
Madeline J. Johnston, Esq.  
Reg. No. 36,174

Date: September 25, 2006

KING & SPALDING LLP  
1180 Peachtree Street  
34<sup>th</sup> Floor  
Atlanta, Georgia 30309  
Tel.: (404) 572-3541